Eli Lilly Signs Multi-Year Deal with Anima Biotech for Translation Inhibitors
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 8 (Table of Contents)
Published: 2 Aug-2018
DOI: 10.3833/pdr.v2018.i8.2341 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Leveraging another source of external innovation, Eli Lilly has partnered with start-up Anima Biotech to discover and develop translation inhibitors for several targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS